Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis

Huan Luo; Peng Wang; Hua Ye; Jianxiang Shi; Liping Dai; Xiao Wang; Chunhua Song; Jianying Zhang; Jitian Li

doi:10.3389/fgene.2020.00789

Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis

Front Genet. 2020 Aug 11:11:789. doi: 10.3389/fgene.2020.00789. eCollection 2020.

Authors

Huan Luo^{1

2}, Peng Wang^{1

2}, Hua Ye^{1

2}, Jianxiang Shi^{2

3}, Liping Dai^{2

3}, Xiao Wang^{2

3}, Chunhua Song^{1

2}, Jianying Zhang^{1

2

3}, Jitian Li⁴

Affiliations

¹ College of Public Health, Zhengzhou University, Zhengzhou, China.
² Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, China.
³ Zhengzhou University, Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou, China.
⁴ Laboratory of Molecular Biology, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital), Zhengzhou, China.

Abstract

Recent reports suggest that microRNAs (miRNAs) may serve as prognostic biomarkers in osteosarcoma. Due to osteosarcoma's early metastasis and poor prognosis, it is very important to find novel prognostic biomarkers for improving osteosarcoma's prognosis. Herein we propose a meta-analysis for serum miRNA's prognostic value in osteosarcoma. In this study, the literature available from PubMed, Web of Science, Embase, and Cochrane Library databases was reviewed. The pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated to evaluate miRNAs prognostic values. A total of 20 studies investigating serum miRNAs were included in this meta-analysis; the initial terminal point of these reports included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and recurrence-free survival (RFS). For prognostic meta-analyses, the pooled HR for terminal events of higher expression of miRNAs and lower expression of miRNAs were 5.68 (95% CI 4.73-6.82, P < 0.05) and 3.78 (95% CI 3.27-4.37, P < 0.05), respectively. Additionally, subgroup analyses were conducted based on the analysis methods applied and clinicopathological features reported. In the pooled analyses, the miRNA expression levels are associated with poor prognosis according to both univariate and multivariate analyses. Furthermore, serum miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) were associated with poor OS and found to be closely correlated with clinical stage and distant metastasis in osteosarcoma. The results illustrate that low or high expression of these specific miRNAs are both potentially useful as prognostic serum biomarkers in osteosarcoma, and miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) may indicate clinical stage and metastasis in this form of cancer.

Keywords: biomarker; meta-analysis; miRNA; osteosarcoma; prognosis; serum.

Publication types

Systematic Review